Renal Connective Tissue Growth Factor Induction in Experimental Diabetes Is Prevented by Aminoguanidine
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The aim of this study was to determine whether aminoguanidine (AG), an inhibitor of advanced glycation, prevents expression of the profibrotic cytokine, connective tissue growth factor (CTGF), as well as accumulation of the previously reported CTGF-dependent matrix protein, fibronectin, in a model of experimental diabetic nephropathy. Diabetic animals were randomly allocated into groups receiving 32 wk of AG or vehicle. Diabetic rats showed increases in CTGF mRNA and protein expression as well as in advanced glycation end-product (AGE) and fibronectin immunostaining, compared with nondiabetic rats. In the diabetic kidney, the increase in CTGF gene and protein expression as well as expression of the extracellular matrix protein fibronectin were prevented by AG. To further explore the relationship between AGEs and mesangial CTGF and fibronectin production, cultured human mesangial cells were exposed in vitro to soluble AGE-BSA and carboxymethyl lysine-BSA, and this led to induction of both CTGF and fibronectin. On the basis of our in vitro findings in mesangial cells linking AGEs to CTGF expression, the known prosclerotic effects of CTGF, and the ability of AG to attenuate mesangial expansion, it is postulated that the antifibrotic effects of AG in this animal model may be partially mediated by CTGF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advanced glycation end-products: A review
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001) · Diabetologia · doi:10.1007/s001250051591 · Cited by 2,597 · cited 1×
“These endproducts of nonenzymatic glycation of protein and lipid, which are increased in diabetic tissues, can induce the cellular formation of cytokines and growth factors, which may themselves then contribute to diabetic renal disease (2, 3).”
BackgroundInteraction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy
Cooper, M. E. (2001) · Diabetologia · doi:10.1007/s001250100000 · Cited by 375 · cited 1×
“Connective tissue growth factor (CTGF) is being increasingly recognized as a possible contributor to diabetic complications (6, 7).”
BackgroundSelf-citationChen, C.-C., Chen, N., & Lau, L. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008087200 · Cited by 305 · cited 1×
“Although CTGF may exert its bioactivity through binding classes of integrin (42, 43) and/or through MAPK pathway activation (44), its exact cellular mechanism of action in mesangial cells is yet to be defined.”
BackgroundJedsadayanmata, A., Chen, C.-C., Kireeva, M. L., Lau, L. F., & Lam, S. C.-T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24321 · Cited by 204
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“Another profibrotic cytokine, connective tissue growth factor (CTGF), is also being considered as a pathogenic mediator of diabetic complications (75, 493, 610).”
BackgroundSelf-citationAdvanced Glycation End Products and Diabetic Complications
Singh, V. P., Bali, A., Singh, N., & Jaggi, A. S. (2014) · The Korean Journal of Physiology & Pharmacology · doi:10.4196/kjpp.2014.18.1.1 · Cited by 1,518
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
“and connective tissue growth factor (15).”
Self-citationExtracellular Matrix Metabolism in Diabetic Nephropathy
Mason, R. M., & Wahab, N. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065640.77499.d7 · Cited by 655
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets
Jun, J.-I., & Lau, L. F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3599 · Cited by 568
The CCN family: a new stimulus package
Brigstock, D. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1780169 · Cited by 502
Candido, R., Forbes, J. M., Thomas, M. C., Thallas, V., Dean, R. G., Burns, W. C., Tikellis, C., Ritchie, R. H., Twigg, S. M., Cooper, M. E., et al. (2003) · Circulation Research · doi:10.1161/01.res.0000065620.39919.20 · Cited by 448
Self-citationGenuth, S., Sun, W., Cleary, P., Sell, D. R., Dahms, W., Malone, J., Sivitz, W., Monnier, V. M., & for the DCCT Skin Collagen Ancillary Study Group (2005) · Diabetes · doi:10.2337/diabetes.54.11.3103 · Cited by 427
Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy
Yamagishi, S.-I., & Matsui, T. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.2.11148 · Cited by 397
Advanced glycation end products and the kidney
Bohlender, J. M., Franke, S., Stein, G., & Wolf, G. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00398.2004 · Cited by 387
Changes in aqueous humor dynamics with age and glaucoma
Gabelt, B. T., & Kaufman, P. L. (2005) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.10.003 · Cited by 377
Role of Advanced Glycation End Products in Diabetic Nephropathy
Forbes, J. M., Cooper, M. E., Oldfield, M. D., & Thomas, M. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077413.41276.17 · Cited by 351
“In addition, we recently demonstrated that soluble AGE including carboxymethyllysine-containing proteins are able to induce the expression of CTGF and fibronectin production in cultured human mesangial cells (22).”
BackgroundSelf-citationAdvanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis
Forbes, J. M., Yee, L. T. L., Thallas, V., Lassila, M., Candido, R., Jandeleit-Dahm, K. A., Thomas, M. C., Burns, W. C., Deemer, E. K., Thorpe, S. R., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1813 · Cited by 314
Self-citationFibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers
Twigg, S. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1991 · Cited by 286
Self-citationForbes, J. M., Thallas, V., Thomas, M. C., Founds, H. W., Burns, W. C., Jerums, G., & Cooper, M. E. (2003) · The FASEB Journal · doi:10.1096/fj.02-1102fje · Cited by 263
Self-citationMcLennan, S. V., Wang, X. Y., Moreno, V., Yue, D. K., & Twigg, S. M. (2004) · Endocrinology · doi:10.1210/en.2004-0436 · Cited by 87
Self-citationCheng, M., Liu, H., Zhang, D., Liu, Y., Wang, C., Liu, F., & Chen, J. (2015) · American Journal of Nephrology · doi:10.1159/000381464 · Cited by 66
The dual face of endogenous α-aminoketones: Pro-oxidizing metabolic weapons
Bechara, E. J. H., Dutra, F., Cardoso, V. E. S., Sartori, A., Olympio, K. P. K., Penatti, C. A. A., Adhikari, A., & Assunção, N. A. (2007) · Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology · doi:10.1016/j.cbpc.2006.07.004 · Cited by 57
“By virtue of diminishing the progression of retinopathy, neuropathy and nephropathy in diabetic rats, preventing protein cross-linking and, thus, the formation of AGEs receptor recognition factors with concomitant dysfunction of endothelial cells, aminoguanidine has been considered a possible therapeutic agent for dia…”
BackgroundRole of diabetes in heart rhythm disorders
Koektuerk, B., Aksoy, M., Horlitz, M., Bozdag-Turan, I., & Turan, R. G. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i3.45 · Cited by 38
Zhao, Z., Ho, L., Wang, J., Qin, W., Festa, E. D., Mobbs, C., Hof, P., Rocher, A., Masur, S., Haroutunian, V., et al. (2005) · The FASEB Journal · doi:10.1096/fj.05-4359fje · Cited by 36
Metadata
- Authors
- Twigg, S. M., Cao, Z., McLennan, S. V., Burns, W. C., Brammar, G., Forbes, J. M., & Cooper, M. E.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2002-12-01
- Volume
- 143
- Issue
- 12
- Pages
- 4907-4915
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1975953243
- Cited by
- 143
- References
- 4
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.